Cosmos Health Inc. Company Summary

Business Overview

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group involved in multiple sectors of the healthcare industry:

• Proprietary Brands: Owner of proprietary pharmaceutical and nutraceutical brands.
• Manufacturing & Distribution: Manufactures and distributes healthcare products including pharmaceuticals, nutraceuticals, biocides, medical devices, and medical supplies.
• Research & Development: Develops innovative medicines, including patented and repurposed drugs, focusing on oncology, CNS, gastrointestinal, and other therapeutic areas.
• Telehealth Operations: Operates a direct-to-consumer telehealth platform called ZipDoctor.

Market & Product Focus

• Markets: Operations primarily in the European Union, UK, and outside the U.S.
• Product Segments:
  • Generics & OTC Pharmaceuticals: Equivalents of branded drugs, marketed in various dosage forms (tablets, capsules, liquids, creams).
  • Proprietary Brands & Nutraceuticals: Brands such as Sky Premium Life® and Mediterranation®, with around 165 SKUs, including vitamins, minerals, herbal extracts, and specialized formulas.
  • Biocides & Medical Supplies: Brands like C-Sept® and C-Scrub® for antimicrobial and antiseptic products.
  • Other Pharmaceutical Products: Melatonin sprays, ear drops, organic infant products.
  • Research & Development: Focuses on novel medicines and drug repurposing platforms like Cloudscreen® for new indications of existing drugs.

Business Operations

• Manufacturing: Certified under European GMP, capable of producing various pharmaceutical forms and personal care products.
• Wholesale & Distribution: Distributes to retail pharmacies, hospitals, clinics, and other healthcare distributors via extensive networks, including automated warehouses.
• Telehealth: ZipDoctor provides 24/7 virtual medical consultations (in English and Spanish) across the U.S.
• Drug Repurposing: Uses the AI-based Cloudscreen® platform to discover new therapeutic uses for approved drugs, with patent filings for multiple sclerosis, gliomas, and hematologic malignancies.
• Research & R&D: Develops new drugs, including weight management pills and cancer therapies, with efforts to accelerate pipeline development.

Customers & Market Size

• Customer Base: Primarily wholesaler and pharmacy clients; no single customer accounts for 10% or more of revenue.
• Geography: 97% of sales in Greece, small percentages in the UK, UAE, Croatia, Bulgaria, Cyprus, Cayman Islands.
• Revenue (FY 2024): approximately $54.4 million.
• Employees: About 149 full-time employees as of December 31, 2024.
• Market Growth:
  • Generic medicines market (2024): $425 billion, projected to reach $875 billion by 2033.
  • Nutraceuticals market (2024): ~$591 billion, projected to reach $1,234 billion by 2034.
  • Oncology drugs (2023): ~$202 billion, projected to hit $518 billion by 2032.
  • Drug repurposing market (2021): ~$24.5 billion, estimated to grow to $30.1 billion by 2028.
  • Obesity & weight management: $163 billion in 2024, expected to reach over $362 billion by 2034.
  • Hospital disinfectants: $75.6 billion by 2033.

Financial Highlights (2024)

• Net Loss: approximately $16.2 million.
• Total Revenue: about $54.4 million.
• Cost of Goods Sold: $50.1 million.
• Gross Profit: $4.3 million.
• Operating Expenses: $19.9 million.
• Net Operating Loss: $15.5 million.
• Cash & Equivalents: $315,105 as of December 31, 2024.
• Employees: 149 full-time staff.
• Customer Count: Approximately 626 stockholders of record (not detailed number of customers).

Strategic Focus

• Expand proprietary brands and product portfolio.
• Grow manufacturing capacity and geographic presence.
• Optimize operations and build global sales/distribution networks.
• Continue innovation through R&D and drug repurposing.
• Leverage AI platform Cloudscreen® for drug discovery.
• Strengthen financial position via capital raising, strategic acquisitions, and operational efficiencies.

Note: The company faces continued risks and is operating at a loss, with substantial doubt about its ability to continue as a going concern.